Table 2. Pathways involved in OPs response.
| Pathway/mechanism | num. genes | CPF | DZN | CPF + DZN | Reference | |||
| Overlap. genes | p-value | Overlap. genes | p-value | Overlap. genes | p-value | |||
| DAF-16 | 541 | 47 | 1.679e-10 | 36 | 2.920e-16 | 29 | 3.242e-11 | [26] |
| ELT-2 | 255 | 30 | 1.779e-10 | 18 | 1.723e-09 | 21 | 3.562e-12 | [34] |
| MDT-15 | 305 | 57 | 1.346e-28 | 29 | 1.319e-17 | 29 | 8.589e-18 | [41] |
| DBL-1/SMA-9 | 320 | 31 | 1.224e-08 | 15 | 7.045e-06 | 22 | 2.829e-11 | [40] |
| PMK-1 | 143 | 13 | 0.00019 | 5 | 0.01267 | 5 | 0.01190 | [36] |
| Cd | 290 | 44 | 9.917e-19 | 44 | 8.403e-35 | 40 | 2.447e-30 | [28] |
Pathway/mechanism investigated were: genes downstream daf-16 (DAF-16), genes regulated by the GATA transcription factor ELT-2 (ELT-2), genes regulated by the Mediator subunit MDT-15 (MDT-15), genes downstream pmk-1 (PMK-1) and cadmium responsive genes (Cd). Number of genes associated with each pathway or mechanism are shown. Overlapping genes are the number of genes belonging to a pathway that are regulated in each treatment. P-values were calculated using hypergeometric test.